WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported a new analysis showing patients treated with YCANTH cleared molluscum contagiosum at about four times the rate of those receiving vehicle, adding evidence for the company’s marketed dermatology treatment as it advances a separate experimental therapy for skin cancer.
The post-hoc analysis pooled results from Verrica’s completed CAMP-1 and CAMP-2 Phase 3 trials of YCANTH, also known as VP-102. The company plans to present the findings this month at dermatology conferences in Las Vegas and Alexandria, Virginia.
Patients receiving VP-102 achieved complete clearance at approximately four times the rate of the vehicle group, with a hazard ratio of 4.06 and a 95% confidence interval of 2.94 to 5.74. Sensitivity analyses produced treatment-effect estimates ranging from 4.05 to 4.19.
By Day 84, Kaplan-Meier estimates showed cumulative complete clearance of 60.1% among patients treated with VP-102, compared with 19.9% for vehicle.
The analysis also examined whether the length of time a patient had molluscum before treatment affected response. Verrica reported that the faster clearance associated with VP-102 persisted regardless of disease duration.
The findings come from a post-hoc pooled analysis rather than a newly conducted clinical trial, a distinction that limits the conclusions that can be drawn beyond the original Phase 3 studies.
Verrica Chief Medical Officer Noah Rosenberg characterized the results as supporting earlier treatment rather than waiting for the infection to resolve without intervention.
“This data, demonstrating more rapid complete clearance with YCANTH, independent of disease duration, gives clinicians a clear, data-driven rationale for early intervention rather than watchful waiting,” Rosenberg said.
Verrica will present the YCANTH analysis at the Fall Clinical Dermatology Conference, scheduled for Oct. 8 through Oct. 11 at the Wynn Las Vegas. The same analysis will be presented at the 2026 Pediatric Dermatology Research Alliance Annual Conference in Alexandria from Oct. 15 through Oct. 17.
The company will also make an encore presentation in Las Vegas of exploratory Phase 2 findings involving VP-315, its investigational oncolytic peptide immunotherapy for basal cell carcinoma.
That analysis examined untreated, non-target tumors in patients who received intratumoral VP-315 in separate target lesions. Verrica is evaluating whether the findings indicate a potential abscopal-like effect, in which treatment of one tumor is associated with effects in untreated tumors elsewhere.
The VP-315 findings were previously presented at the 2026 Society for Investigative Dermatology Annual Meeting.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.